due to cell death method calculation. As a note, we determined specific cell killing by APO866 to avoid any bias in apoptosis and autophagy inhibition experiments (Nahimana et al., Figure 4 and Figure S1), and we additionally presented raw data of cell death–associated parameters for primary cultures from several hematologic cancers highlighting the broad efficacy of APO866 (Nahimana et al., Figures 1.2). We have now expanded such determination on all primary hematologic cancer cells originally reported. Results are quite similar to fdc (fraction of dead cells; Figure 1B). Several explanations may account for the difference observed between our data and those from Cea et al. First, our patient samples used to investigate the killing effect of APO866 had cell viability of more than 85% after thawing. High spontaneous cell death may skew specific cell death rate determination. Second, we determined annexin V-7AAD expressions on gated tumoral cells using cell lineage specific labeled antibodies, information we do not know from Cea and colleagues who used samples containing up to 30% nontumoral cells. Third, we would be interested to know in which culture conditions Cea and colleagues determined APO866 killing activity, because they can influence killing efficacy of antimeabolite cytotoxic agents such as APO866. As shown in Figure 1C, we observed variability in APO866 cell killing efficacy according to cell culture. This latter point also stresses the need to validate in vitro results with in vivo data, where we found that APO866 exerts potent antitumor activities in vivo xenochimeric models of human acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and lymphoblastic lymphomas without significant toxicities to the animals.

In summary, the cell-killing effect of APO866 on primary hematologic cancer cells is not dependent on the calculation methods of cell death. The confirmation of the MTT data by other cell cytotoxicity readouts demonstrates that APO866 is a potent anticancer agent in numerous hematologic malignancies.

Aimable Nahimana, Dominique Aubry, Steven Butcher, and Michel A. Duchosal

**Contribution:** A.N. designed, executed, analyzed experiments and wrote the letter; D.A. and S.B. analyzed results and wrote the paper; and M.A.D. designed and analyzed experiments and wrote the paper.

**Conflict-of-interest disclosure:** S.B. is employed by TopoTarget, Denmark SA. TopoTarget has licensed the worldwide development and marketing rights to APO866 from Astellas. The remaining authors declare no competing financial interests.

**Correspondence:** Michel A. Duchosal, MD, Service of Hematology, University Hospital of Lausanne (CHUV), 46 rue du Bugnon, 1011 Lausanne, Switzerland; e-mail: michel.duchosal@chuv.ch.

**Reference**


**To the editor:**

**Recipient plasmacytoid DCs are not required to prime allogeneic T-cell responses after BMT**

We read with interest the elegant studies of Koyama and colleagues in which they demonstrate the ability of recipient conventional dendritic cells (cDCs) and plasmacytoid DC (pDCs) to prime allogeneic T-cell responses and initiate graft-versus-host disease (GVHD) when adoptively transferred into irradiated MHC class II−/− recipients. Intriguingly, they report that the ability of recipient pDCs to prime allogeneic donor T-cell responses is dependent on their activation by the inflammatory environment generated by total body irradiation (TBI).

We recently investigated the role of pDCs in GVHD, and in the course of this study we were surprised to observe that recipient pDCs were exquisitely sensitive to myeloablative doses of TBI. As such, we were intrigued by the paradox presented by Koyama et al’s report, that is, that pDCs have the capacity to present alloantigen only when activated by TBI; but in response to TBI, we have observed their complete elimination within 24 hours (Figure 1A).

To eliminate the possibility that the observed sensitivity of lymphoid organ pDCs to TBI simply reflects their trafficking into additional sites, we administered the pDC-depleting 120G8 mAb to irradiated B6D2F1 mice before the transplantation of allogeneic T cells. Equivalent donor T-cell responses were observed when mice treated with TBI were administered pDC-depleting or control antibody (Figure 1B,C). These data confirm that pDCs are systemically depleted by TBI (or alternatively, that residual pDCs remain in nonlymphoid tissue, but make no contribution to alloreactivity), and therefore strongly argue against the assertion that host pDCs play a significant role in the presentation of host alloantigen to donor T cells after TBI conditioning.

It is nonetheless possible that pDCs may play a role in priming allogeneic donor T-cell responses after non–TBI-based transplantation. We therefore also examined the effect of pDC depletion on the priming of allogeneic parental T cells when transferred into nonirradiated F1 recipients treated with NK1.1 to eliminate antidonor hybrid resistance. Consistent with the requirement for pDC activation by TBI demonstrated in the Koyama paper, no difference in donor T-cell responses were seen in the presence or absence of recipient pDCs (Figure 1B,C). As an intriguing aside, the only statistically significant finding was that donor cells injected into TBI-treated mice underwent significantly less proliferation than in the nonirradiated setting. This likely reflects the 10-fold greater numbers of host antigen-presenting cells (APCs) remaining at the time of bone marrow transplantation (BMT) in nonirradiated recipients. Because host pDCs fail to prime donor T cells in the absence of TBI conditioning and TBI itself rapidly depletes host pDCs, we suggest that this APC subset is unlikely to be an important population in the initiation of GVHD.

Kate A. Markey, Kelli P. A. MacDonald, and Geoffrey R. Hill

**Conflict-of-interest disclosure:** The authors declare no competing financial interests.

**Correspondence:** Dr Geoffrey R. Hill, Bone Marrow Transplantation Laboratory, Queensland Institute of Medical Research, 300 Herston Rd, Herston, QLD, Australia, 4006; e-mail: geoff.hill@qimr.edu.au.
Figure 1. Effects of recipient pDCs on donor T-cell priming. (A) B6D2F1 mice were irradiated with 1300 cGy in 2 split doses of 650 cGy, 3 hours apart. At the time of the second irradiation, mice were injected with 1 mg of the pDC-depleting mAb 120G8 or isotype control antibody MAC49. Twenty-four hours later (the usual time of transplant), bone marrow and spleen were examined for pDC and cDC content. Anti–PDCA-1 (Miltenyi Biotec, Bergisch Gladbach, Germany) and CD11c (Biolegend, San Diego, CA) mAbs were used for flow cytometric analysis. DCs were enriched using density-gradient centrifugation before examination. Representative plots shown. (B) B6D2F1 mice received TBI or 1 mg anti-NK1.1 as pretransplant conditioning, followed by 120G8 or control mAb. Purified carboxyfluorescein succinimidyl ester (CFSE)-labeled B6 CD45.1 CD4 T cells were injected and proliferation of splenic T cells analyzed by CFSE dilution 3 days later. Cells were stained with CD45.1, CD4, and the vital dye 7-AAD. Histograms shown are gated on live CD45.1 CD4 T cells. No difference in alloresponse was observed in the absence of pDC in either the irradiated or nonirradiated setting. (C) Modfit software (Verity Software House, Topsham, ME) was used to quantify the extent of donor T-cell proliferation. Calculated proliferation index = Σ all cells/computed number of parent cells. Data shown representative of 3 experiments, with n = 12 and n = 7 in respective TBI and NK1.1 groups. P = .37 irradiated control mAb versus irradiated 120G8. P = .31 nonirradiated control mAb versus nonirradiated 120G8. *P < .001 irradiated versus nonirradiated control and 120G8 mAb treated.

References

Recipient plasmacytoid DCs are not required to prime allogeneic T-cell responses after BMT

Kate A. Markey, Kelli P. A. MacDonald and Geoffrey R. Hill

Updated information and services can be found at:
http://www.bloodjournal.org/content/113/23/6038.full.html
Articles on similar topics can be found in the following Blood collections

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml